27,780 Alzheimer's and dementia studies in plain English, each scored out of 100.
Adults were more likely than children to screen positive for a single autoantibody (4.0% vs. 2.6%) but less likely for multiple autoantibodies (0.83% vs. 2.8%; P < 0.001). 5 key findings →
Participants: 135,914 Evidence: low
Full summary, score breakdown and related studies → Original source Free full text
A total of 346 of 374 (92.5%) intervention arm participants received some intervention (reach), and 305 of 374 (81.6%) attended ≥5 main sessions (predefined as adhering: dose). 5 key findings →
Design: randomized controlled trial Participants: 346 Evidence: high
Full summary, score breakdown and related studies → Original source Free full text
The highest-risk group (Q4) shows a 2.8-fold increased risk of Alzheimer’s disease, a 6.4-fold risk of multiple sclerosis, and a 2.4-fold higher mortality risk. 5 key findings →
Design: cohort study Participants: 38,967 Evidence: moderate
Full summary, score breakdown and related studies → Original source Free full text
HI is associated with increased risk of developing dementia in older adults. 3 key findings →
Evidence: high
Full summary, score breakdown and related studies → Original source Free full text
Only 11 putative risk factors for delirium are supported by either strong or moderate level of evidence. 1 key finding →
Evidence: low
Full summary, score breakdown and related studies → Original source Free full text
Lipid-lowering agent use was associated with a lower risk of dementia, and specifically of Alzheimer disease, in those younger than 80 years. 5 key findings →
Design: cohort study Participants: 492 Evidence: moderate
Full summary, score breakdown and related studies → Original source Full text may need a subscription
Adults with Down syndrome develop the neuropathological hallmarks of Alzheimer's disease and are at very high risk of developing early-onset dementia, which is now the leading cause of death in this population. 1 key finding →
Evidence: low
Full summary, score breakdown and related studies → Original source Free full text
Delirium and dementia are two frequent causes of cognitive impairment among older adults and have a distinct, complex and interconnected relationship. 1 key finding →
Evidence: low
Full summary, score breakdown and related studies → Original source Free full text
Frailty, a critical intermediate status of the aging process that is at increased risk for negative health-related events, includes physical, cognitive, and psychosocial domains or phenotypes. 3 key findings →
Design: cross-sectional Evidence: moderate
Full summary, score breakdown and related studies → Original source Free full text
A population-based longitudinal study in Sweden, the Kungsholmen Project A random sample of 370 nondemented persons, aged 75 years and older and not treated with B(12) and folate, was followed for 3 years to detect incident AD cases. 1 key finding →
Design: longitudinal study Evidence: moderate
Full summary, score breakdown and related studies → Original source Full text may need a subscription
Although statin use might be less frequent in those with prevalent dementia, we found no association between statin use and subsequent onset of dementia or AD. 3 key findings →
Design: cross-sectional Participants: 4,895 Evidence: low
Full summary, score breakdown and related studies → Original source Full text may need a subscription
Our results provide additional evidence that depressive symptoms determine an additive risk effect to the progression to dementia in subjects with MCI. 5 key findings →
Design: meta-analysis Evidence: high
Full summary, score breakdown and related studies → Original source Full text may need a subscription
A thinner RNFL was associated with worse cognitive performance on baseline assessment. 5 key findings →
Participants: 38 Evidence: moderate
Full summary, score breakdown and related studies → Original source Free full text
Few teeth without dentures and absence of a regular dentist, not poor mastication and poor attitudes toward dental health, were associated with higher risk of dementia onset in the older Japanese cohort even after adjustment for available covariates. 4 key findings →
Design: cohort study Participants: 220 Evidence: moderate
Full summary, score breakdown and related studies → Original source Full text may need a subscription
These results should be confirmed with a randomized clinical trial of a centrally active ACE inhibitor in the prevention of cognitive decline and dementia. 5 key findings →
Participants: 1,054 Evidence: high
Full summary, score breakdown and related studies → Original source Free full text
Some well-known risk factors for AD were confirmed in this study and potential new risk factors were identified. 3 key findings →
Design: longitudinal study Participants: 36 Evidence: moderate
Full summary, score breakdown and related studies → Original source Full text may need a subscription
From 11 295 literature citations associated with 10 PICO questions, 20 relevant studies were identified. 1 key finding →
Participants: 13 Evidence: low
Full summary, score breakdown and related studies → Original source Full text may need a subscription
Dementia has reached epidemic proportions, with an estimated 4.6 million new cases worldwide each year. 5 key findings →
Design: cross-sectional Participants: 34,000 Evidence: high
Full summary, score breakdown and related studies → Original source Full text may need a subscription
Higher midlife fitness levels seem to be associated with lower hazards of developing all-cause dementia later in life. 5 key findings →
Design: cohort study Evidence: moderate
Full summary, score breakdown and related studies → Original source Free full text
In SURMOUNT-5, treatment with tirzepatide was associated with greater predicted 10-year CVD risk reduction compared with semaglutide. 3 key findings →
Design: randomized controlled trial Evidence: high
Full summary, score breakdown and related studies → Original source Free full text
Among the 11 risk factors, educational attainment has the greatest impact on dementia risk and cognitive decline. 5 key findings →
Design: longitudinal study Participants: 30,113 Evidence: moderate
Full summary, score breakdown and related studies → Original source Free full text
Aging is associated with physiological changes that increase the risk of falls, impacting functional independence and quality of life. 4 key findings →
Design: randomized controlled trial Participants: 40 Evidence: high
Full summary, score breakdown and related studies → Original source Free full text
Diagnosis of AD was associated inversely with FTI by itself and after adjustments for age, education, smoking status, body mass index, diabetes, any cancer diagnoses, and hormone supplements. 5 key findings →
Design: longitudinal study Evidence: moderate
Full summary, score breakdown and related studies → Original source
In the intention-to-treat analysis, dementia risk was not different between GLP1-RA and DPP4i initiators (hazard ratio [HR] 0.95, 95% confidence interval [CI] 0.87–1.04; rates: 6.29 versus 6.64 per 1000 person-years; mean follow-up: 6.54 years); however, continuous GLP1-RA versus DPP4i use was associated with a 21% lower risk (HR 0.79, 95% CI 0.64–0.97; rates: 3.64 versus 4.82; mean follow-up: 2.71 years). 4 key findings →
Design: cohort Participants: 107,424 Evidence: moderate
Full summary, score breakdown and related studies → Original source Free full text
Antihypertensive treatment significantly improved cognitive function scores (SMD, 0.06; 95% CI, 0.03-0.09; P Conclusions and implications Antihypertensive therapy significantly improves cognitive function with moderate certainty evidence, supporting its use for cognitive protection in older adults with hypertension. 2 key findings →
Design: meta-analysis Participants: 16,823 Evidence: moderate
Full summary, score breakdown and related studies → Original source Full text may need a subscription
Free full text links and the Full text may need a subscription label come from Unpaywall, Europe PMC and OpenAlex records of free copies, checked 10 Oct 2026. A study with neither is unknown, not paywalled. Show only studies that are free to read
This is alzhub's own score. It is not an official metric, not an impact factor, and no journal, publisher or ranking body endorses it. We built it so that a reader who is not a scientist can tell a landmark trial from a conference abstract without having to already know the difference. Every point comes from one of 20 components, all of them printed on the study itself, so you can disagree with our arithmetic rather than having to trust the total.
Journals are placed in ordered tiers, never given a numeric impact factor — we could not verify current impact factors from a source we control, and an invented one would be worse than none. Tier 1 is the top-tier general journals (NEJM, The Lancet, JAMA, Nature, Science, Nature Medicine); tier 2 is the leading specialty journals; tier 3 is every other peer-reviewed journal. A separate part scores how much the journal's own papers are cited, which tells the tier-3 journals apart.
Two rules we don't bend. First, we never fill in a missing value: if a record does not state a sample size or a design, that component scores zero, and if we simply have no data for a part, such as a citation count, that part is left out and the study is scored on the parts we could check. The study card says which. Second, anything that is not a peer-reviewed article is capped at 16/100 and carries a warning chip — so a conference abstract or a company press release can never outrank a peer-reviewed paper, no matter how good it looks.
We rank a rigorous null result — a good trial showing that something does not work — above an early positive finding. Someone deciding whether to buy a supplement is served by that, and the rigour is already counted by the design and journal components.
The score is computed from the published data alone and is reproducible: the same file always yields the same numbers.
See the whole rubric drawn out → — four charts covering all 27,780 studies: how the scores are spread and where the cap bites, which of the 20 components the library is strong and weak on, which subjects rest on stronger evidence, and what kinds of study each subject is actually built from.
This is a large sample of the Alzheimer's literature, not an exhaustive index of it. It holds 27,780 records, built mostly from automated pulls of Europe PMC (61.1% of the library) and OpenAlex (18.3%), plus smaller pulls from PubMed, Crossref and medRxiv. If a study, a drug, or a finding isn't here, that is not evidence it doesn't exist in the literature — it may simply not have been pulled in yet.
1,034 records (3.7% of the library) are not peer-reviewed — 962 of those are preprints posted before any journal review, and the rest are conference abstracts, regulatory notices and reports. Every study card on this page states its status plainly, and the score above is capped for anything that isn't a peer-reviewed article.
See the full, machine-readable breakdown of this library's coverage →